Publicaciones archivos - Página 10 de 20

Seguiment de carcinoma urotelial per FISH. És sempre útil?

Beatriz García-Peláez¹, Ruth Román^1,2,Isabel Trias³, Carme Pubill^3, Myriam Gorriz³, Montse Verdú^1,3, Natalia Rodón^1, Mercè Pujol¹, Josep M. Banús⁴ i Xavier Puig^1,2,3.

¹BIOPAT. Biopatologia Molecular SL, Grup Assistència. ²Hospital de Barcelona-SCIAS, Grup Assistència. ³ Histopat Laboratoris. ⁴ Institut Català d’Urologia i Nefrologia. Barcelona.

Introducció

Nombrosos autors han demostrat l’increment de sensibilitat de la hibridació “in situ” (FISH) tant en el diagnòstic com en el seguiment del carcinoma urotelial (CU) davant la citologia urinària. Mes recentment s’estan presentant nous treballs que estudien l’efecte anticipador de […]

Alberto 2012-06-08T14:09:00+00:00

Estudi del gen EGFR en carcinoma escamós i adenocarcinoma de pulmó.

R Roman¹*, N Rodon¹*, M Verdu^1,3*, B Garcia¹ , M Pujol¹ i X Puig^1,2,3.

¹BIOPAT. Biopatologia Molecular, SL, Grup Assistència; ²Hospital de Barcelona, SCIAS, Grup Assistència; ³Histopat Laboratoris. Barcelona.*(co-autors).

Introducció

Les mutacions en el receptor del factor de creixement epidèrmic (EGFR) i, en menor mesura, l’augment en el nombre de còpies, s’han correlacionat amb resposta a inhibidors del domini tirosina cinasa (TKIs) d’aquest receptor i augment de la supervivència. La majoria d’aquests estudis s’han dut a terme en sèries d’adenocarcinomes (AC), ja que […]

Alberto 2012-06-08T14:04:55+00:00

Epidermal growth factor receptor copy number variations, but not EGFR or KRAS mutations, are frequent in lung squamous cell carcinomas

R Roman¹, N Rodon¹, M Verdu^1,3, B Garcia¹ , M Pujol¹, M. Calvo ⁴ and X Puig ^1,2,3.

¹BIOPAT.Biopatologia Molecular, SL, Grup Assistencia, Barcelona, Spain; ²Hospital de Barcelona, SCIAS, Grup Assistencia, Barcelona, Spain; ³Histopat Laboratoris, Barcelona, Spain and ⁴Statistics Department, Universitat Barcelona, Barcelona, Spain.

Background: Epidermal growth factor receptor (EGFR) mutations, and to a lesser extent EGFR copy number variations, have been correlated with response to EGFR tyrosine kinase inhibitors (TKIs). In contrast, KRAS mutations have been recently associated with resistance to […]

Alberto 2012-03-14T23:10:34+00:00

Highly sensitive real-time PCR for the detection of EGFR mutations in lung adenocarcinoma. Is it worth it?

Rodon Natalia¹, Roman Ruth¹, Verdu Montse^1,3, Garcia Beatriz¹, Pujol Merce¹ and Puig Xavier ^1,2,3.

¹BIOPAT.Biopatologia Molecular, SL, Grup Assistencia, Barcelona, Spain; ²Hospital de Barcelona, SCIAS, Grup Assistencia, Barcelona, Spain; ³Histopat Laboratoris, Barcelona, Spain.

Background: Mutations involving the epidermal growth factor receptor (EGFR) correlate with responsiveness to tyrosine kinase inhibitors (TKIs), which significantly improves patient survival in lung adenocarcinoma (AC). These mutations are described to be more frequent in non-mucinous lepidic adenocarcinomas (nmBAC). The unquestionable importance of determining the presence of these mutations, even in samples with […]

Alberto 2012-03-14T23:08:26+00:00

ERG Expression in 175 Prostatic Carcinomas and 270 Carcinomas from Different Primary Sites

Verdu Montse^1,3, Roman Ruth¹, Calvo Miquel⁴, Rodon Natalia¹, Garcia Beatriz¹, Pujol Merce¹ and Puig Xavier^1,2,3.

¹BIOPAT.Biopatologia Molecular, SL, Grup Assistencia, Barcelona, Spain; ²Hospital de Barcelona, SCIAS, Grup Assistencia, Barcelona, Spain; ³Histopat Laboratoris, Barcelona, Spain; ⁴Universitat de Barcelona(UB), Statistics Dpt., Barcelona, Spain;

Background: ERG gene rearrangement, detected by FISH or RT-PCR, has been identified as a highly specific alteration, present in 40-50% of prostate carcinomas (PCa). Recent studies describe a novel anti-ERG antibody, whose positive staining by immunohistochemistry (IHC) highly correlates with the […]

Alberto 2012-03-14T23:03:48+00:00

Previous 8 9 10 11 12 Next